UBS Group AG Raises Position in Kestra Medical Technologies, Ltd. $KMTS

UBS Group AG grew its holdings in shares of Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) by 34.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 270,058 shares of the company’s stock after purchasing an additional 69,908 shares during the period. UBS Group AG owned approximately 0.46% of Kestra Medical Technologies worth $7,162,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Farther Finance Advisors LLC purchased a new stake in shares of Kestra Medical Technologies during the 4th quarter valued at $31,000. China Universal Asset Management Co. Ltd. acquired a new stake in Kestra Medical Technologies during the 3rd quarter worth about $48,000. BNP Paribas Financial Markets grew its stake in Kestra Medical Technologies by 148.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 2,738 shares of the company’s stock valued at $65,000 after purchasing an additional 1,638 shares during the last quarter. Brown Brothers Harriman & Co. increased its holdings in shares of Kestra Medical Technologies by 26.8% in the third quarter. Brown Brothers Harriman & Co. now owns 3,104 shares of the company’s stock valued at $74,000 after purchasing an additional 656 shares during the period. Finally, New York State Common Retirement Fund purchased a new position in shares of Kestra Medical Technologies in the second quarter worth about $93,000.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the company. BTIG Research reiterated a “buy” rating and issued a $32.00 target price on shares of Kestra Medical Technologies in a research report on Tuesday, April 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Kestra Medical Technologies in a research report on Monday, March 23rd. Finally, The Goldman Sachs Group reduced their price objective on shares of Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating for the company in a research report on Thursday, April 9th. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $27.40.

Insiders Place Their Bets

In other Kestra Medical Technologies news, insider Brian Daniel Webster sold 15,000 shares of the firm’s stock in a transaction that occurred on Friday, May 15th. The shares were sold at an average price of $20.96, for a total transaction of $314,400.00. Following the sale, the insider owned 334,786 shares of the company’s stock, valued at approximately $7,017,114.56. This trade represents a 4.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold a total of 45,000 shares of company stock worth $919,050 over the last 90 days. 3.60% of the stock is currently owned by company insiders.

Kestra Medical Technologies Trading Down 1.2%

NASDAQ KMTS opened at $19.59 on Tuesday. The firm has a 50 day simple moving average of $20.65 and a 200-day simple moving average of $23.86. The company has a debt-to-equity ratio of 0.15, a quick ratio of 7.32 and a current ratio of 7.32. Kestra Medical Technologies, Ltd. has a one year low of $13.25 and a one year high of $30.00. The firm has a market cap of $1.14 billion, a price-to-earnings ratio of -4.95 and a beta of 0.82.

Kestra Medical Technologies (NASDAQ:KMTS) last issued its quarterly earnings results on Tuesday, March 17th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.01). Kestra Medical Technologies had a negative return on equity of 65.49% and a negative net margin of 171.87%.The firm had revenue of $24.55 million during the quarter. The firm’s quarterly revenue was up 62.7% on a year-over-year basis. Equities research analysts anticipate that Kestra Medical Technologies, Ltd. will post -2.34 EPS for the current fiscal year.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.